Summit Therapeutics Inc. (SMMT) shares climbed 6.8% to $15.80 as of November 4, 2026, a significant gain from the prior close of $14.80. BestStocks flagged the session as a major change for SMMT. Below, we break down what changed for SMMT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
SMMT climbed 6.8% to $15.80
SMMT climbed 6.8% in its latest session, moving from $14.80 to $15.80.
ActivityLow confidence
Rel. volume
1.1×
Normal
Vs peers
—
No comparable peers
Market cap
$12.6B
NASDAQ Global Market
Analyst target
$31
+96.2% vs price
Price chart
Oct 5 – Nov 3
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Summit Therapeutics Inc. investors
For Summit Therapeutics Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 6.8% price move. Weighing against that: Summit Therapeutics declined 5.56% to $14.61 despite partner Akeso announcing positive Phase III HARMONi-GI1 results showing ivonescimab plus chemotherapy achieved overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer treatment (Business Wire, 2026-10-25); Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47. Wall Street's consensus price target sits at $31.00, implying +96.2% upside from $15.80. Over the past 90 days analysts logged 3 upgrades and 0 downgrades. BestStocks rates the overall signal quality low (59/100). With earnings roughly 5 days out, the next report is the most likely near-term test of the move.
SMMT price reaction
SMMT last traded at $15.80, up $1.00 (+6.76%) from the previous close of $14.80. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $14.50 and $17.95, and it currently sits about 38% of the way up that band.
Bullish and bearish analyst opinions on Summit Therapeutics Inc. (SMMT)
The consensus analyst price target on Summit Therapeutics Inc. (SMMT) is $31.00, 96.2% above the recent $15.80. Over the past 90 days analysts logged 3 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on SMMT line up.
▲ The bullish case
+Wall Street's consensus price target of $31.00 implies +96.2% upside from $15.80.
+The Street's most bullish target is $41.00 (+159.5%).
+3 analyst upgrades in the past 90 days, most recently Jefferies to Buy (2026-09-09).
+Material positive event.
+Strong 6.8% price move.
▼ The bearish case
−Summit Therapeutics declined 5.56% to $14.61 despite partner Akeso announcing positive Phase III HARMONi-GI1 results showing ivonescimab plus chemotherapy achieved overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer treatment (Business Wire, 2026-10-25).
−Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 3, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Summit Therapeutics Inc. (SMMT) moved -6.74% from $15.88 to $14.81 on 2026-11-02. We checked news, earnings, analyst updates, and filings — no company-specific catalyst was identified. The decline appears driven by broader biotech sector risk-off sentiment and profit-taking, with volume near its 5-day average.
Material / Earnings2026-10-27+5.7%
Summit Therapeutics Inc. (SMMT) moved +5.72% from $14.50 to $15.33 on 2026-10-27, driven by news that partner Akeso's ivonescimab plus chemotherapy demonstrated superior overall survival versus durvalumab in advanced biliary tract cancer. The move reflects continued momentum following Summit's $2 billion equity investment completion with AstraZeneca earlier in October.
Summit Therapeutics declined 5.56% to $14.61 despite partner Akeso announcing positive Phase III HARMONi-GI1 results showing ivonescimab plus chemotherapy achieved overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer treatment (Business Wire, 2026-10-25). The stock fell despite the clinical win, suggesting investors may be pricing in execution risk, regulatory pathway uncertainty, or broader market headwinds. Volume of 2.0M shares trades at 0.81x historical average for this time of session — within normal range.
News2026-10-23-0.5%
Summit Therapeutics partners with Lunit to use AI-powered SCOPE IO platform for tumor microenvironment analysis in immuno-oncology.
News2026-10-22-1.8%
Summit will present ivonescimab data across 10 presentations at ESMO 2026 Congress in October.
News2026-10-21-1.6%
Summit Therapeutics enters Phase II/III trial with ECOG-ACRIN evaluating ivonescimab for first-line biliary tract cancer.
Summit Therapeutics Inc. moved +6.19% intraday from $14.63 to $15.54. Summit Therapeutics (SMMT) stock is up about 6% on October 19, 2026, driven by a new clinical trial announcement and corporate filings ahead of upcoming catalysts.Key reasons for the move include: - New Phase II Kidney Cancer Study: Summit announced the opening of global clinical trial sites for a multiregional Phase II study evaluating its lead bispecific antibody, ivonescimab , in previously untreated advanced clear cell renal cell carcinoma (ccRCC) in collaboration with Akeso Inc. - Proxy Statement / Share Proposal: The company filed a definitive proxy statement proposing to double its authorized common stock to 2 billion shares ahead of a special shareholder meeting scheduled for November 4, 2026. - Pre-Catalyst Momentum: Investor focus remains high following AstraZeneca’s recently completed $2 billion strategic investment and upcoming milestones, including the European Society for Medical Oncology (ESMO) presentations and a pivotal FDA decision for ivonescimab in lung cancer scheduled for November 14, 2026. Would you like more details on ivonescimab's clinical trial pipeline or the upcoming November 14 FDA decision?
News2026-10-19+6.4%
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
In-depth SMMT event analyses
Permanent, dated analyses of SMMT's most significant sessions.
Why did Summit Therapeutics Inc. (SMMT) stock move?
SMMT climbed 6.8% to $15.80. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did SMMT stock rise?
SMMT gained 6.76% ($1.00) versus the prior close of $14.80, last trading at $15.80 on 1.1× average volume.
When is Summit Therapeutics Inc.'s next earnings date?
SMMT's next earnings report is estimated for 2026-11-09 — about 5 days away.
What is the analyst price target for SMMT?
The consensus analyst price target for SMMT is $31.00, about 96.2% above the current $15.80. Over the past 90 days, analysts recorded 3 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks SMMT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared SMMT-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for SMMT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
